Analysis in order to estimate the blood vessel contrast reaction for the lipid decrease remedy in the patient

摘要

The present invention relates to an assay for testing the genetic predisposition to respond to lipid-lowering therapy in patients with coronary artery disease (CAD), comprising identifying the presence or absence of a TaqIB restriction site in intron 1 in both alleles of the cholesteryl ester transfer protein (CETP) gene by suitable molecular biological techniques; and correlating the presence of the restriction site on one or both alleles with a high or intermediate, susceptibility for lipid-lowering therapy. The invention further relates to a testkit for performing the assay and to a cholesterol ester transfer protein (CETP) gene marker for identifying individuals that may or may not be susceptible for lipid-lowering therapies.